<DOC>
	<DOCNO>NCT01502280</DOCNO>
	<brief_summary>Gliomas common primary brain tumor , yet remain challenge effectively treat . Mounting evidence suggest survival improves great tumor removal , yet able complete removal difficult due tumor 's infiltrating nature . 5-aminolevulinic acid ( 5-ALA ) natural compound , patient take mouth 3 hour surgery , selectively take glioma cell cause red/pink fluorescence ( glow ) blue light allow tumor margin see course surgery . While compound use standard-of-care agent Europe , remain test Food Drug Administration ( FDA ) . A recent clinical trial Germany , however , demonstrate significant improvement rate complete resection certain brain tumor ( 65 % vs. 34 % ) . The Barrow 5-ALA Intraoperative Confocal ( BALANCE ) Trial measure effect 5-ALA amount glioma tumor removal . To improve usefulness 5-ALA , new special microscope fit blue light , use magnify microscopic fluorescence tumor margin . The investigator ' hypothesis 5-ALA fluorescence use special microscope surgery greatly low amount tumor leave behind .</brief_summary>
	<brief_title>Fluorescence-guided Surgery Low- High-grade Gliomas</brief_title>
	<detailed_description>Gliomas common primary brain tumor , yet associate 12-14 month overall survival United States . Mounting evidence suggest survival improves great extent resection , yet achieve complete radiographic resection challenge due tumor 's infiltrating nature . Oral 5-aminolevulinic acid ( 5-ALA/Gliolan® ) natural compound , administer patient within 3 hour prior surgery , selectively metabolize glioma cell induce red/pink fluorescence blue light facilitates intraoperative identification tumor margin . While compound use standard-of-care agent Europe , remain examination Food Drug Administration ( FDA ) . A recent multicenter randomize , single-blind , control study Germany demonstrate significant improvement rate complete resection high-grade glioma , compare conventional microneurosurgery ( 65 % vs. 34 % ) ( Stummer et al. , Lancet Oncology 2006 ) . Patients presume newly-diagnosed glioma enter trial . On basis expect extent resection ( low vs. high ) , stratify one 2 group - Group 1 ( expect high extent resection ) Group 2 ( expect low extent resection ) . Following stratification , patient newly-diagnosed disease randomize receive either study drug ( 5-ALA/Gliolan® ) placebo ( ascorbic acid ) prior surgery . Those previous biopsy without treatment eligible randomization . Intraoperatively , 5-ALA/Gliolan® patient undergo resection combine fluorescence microscopy confocal microscopy . Placebo patient undergo resection standard light microscopy . Postoperatively , patient MRI scan without contrast within 48 hour surgery . Subsequent analysis patient include assessment primary endpoint , , volume residual disease ( VRD ) volumetrically quantify tumor surgery use T1-weighted contrast-enhancement ( high-grade glioma ) T2-weighted hyperintensity ( low-grade glioma ) . Similarly , volumetric extent resection also measure . Other secondary endpoint include overall survival ( OS ) , progression-free survival ( PFS ) , National Institute Health Stroke Scale ( NIHSS ) ( collect baseline , 7-10 day post-op 6 , 12 , 18 , 24 month post op ) . The Barrow 5-ALA Intraoperative Confocal ( BALANCE ) study quantify impact 5-ALA/Gliolan ( R ) low- high-grade glioma extent resection . To enhance efficacy 5-ALA/Gliolan ( R ) , particularly low-grade glioma fluoresce less vigorously due comparatively low cellular metabolism , intraoperative confocal microscopy use amplify microscopic fluorescence tumor margin . The investigator ' hypothesis , low- high-grade glioma , 5-ALA/Gliolan ( R ) fluorescence conjunction intraoperative confocal microscopy significantly low VRD . Goals : 1 . To determine impact intraoperative fluorescence confocal microscopy volume residual disease follow resection newly-diagnosed glioma . Sub-goals : 1 . To assess feasibility utility combine intraoperative fluorescence confocal microscopy . 2 . To determine impact combine approach improve volumetric extent resection . 3 . To determine impact combine approach improve overall survival 6-month progression-free survival .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<criteria>Presumed newlydiagnosed supratentorial glioma ( previous biopsyonly/no adjuvant therapy eligible randomization ) Age &gt; 18 year Normal bone marrow function ( WBC &gt; 3000 , Platelets &gt; 100,000 ) Infratentorial tumor Pregnancy Hypersensitivity 5aminolevulinic acid hydrochloride porphyrins History photosensitivity , porphyria , exfoliative dermatitis Hepatic dysfunction last 12 month ( define AST , ALT , ALP , bilirubin &gt; 2.5 x normal ) Serum creatinine &gt; 180 µmol/L Estimated Glomerular Filtration Rate ( eGFR ) &lt; 60 ml/min/1.73m2 Inability undergo MRI scan contrast</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>extent resection</keyword>
	<keyword>Glioma</keyword>
	<keyword>5-ALA</keyword>
	<keyword>tumor fluorescence</keyword>
	<keyword>confocal microscopy</keyword>
</DOC>